Novel uricosurics.
Rheumatology (Oxford)
; 57(suppl_1): i42-i46, 2018 01 01.
Article
en En
| MEDLINE
| ID: mdl-29272511
ABSTRACT
Objective:
According to recent guidelines, the mainstay of urate-lowering therapies remains xanthine oxidase inhibition. However, some patients with gout show failure to achieve the predefined target of 5-6 mg/dl with xanthine oxidase inhibitors alone, so alternative drugs are needed. The aim of this study was to review studies of novel drugs targeting uric acid transporter 1 (URAT1) and/or other urate transporters for the management of gout.Methods:
MeSH terms were used to identify phase 2/3 trials assessing the efficacy of novel uricosurics. A narrative review of novel drugs targeting URAT1 and/or other urate transporters for the management of gout is provided.Results:
Lesinurad is a recently approved uricosuric that inhibits URAT1 and the organic ion transporter organic anion transporter 4 (OAT4). Phase 3 trials showed that lesinurad, combined with allopurinol or febuxostat, is a potent urate-lowering therapeutic with an acceptable safety profile. Arhalofenate, another emerging uricosuric, also interacts with URAT1 and organic anion transporter 4. Phase 2 trials suggested that it can both lower serum UA levels and reduce the risk of flares.Conclusions:
New drugs inhibiting URAT1 should cover the unmet need for patients with failure to respond or with contraindications to xanthine oxidase inhibitors.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Ácido Úrico
/
Supresores de la Gota
/
Manejo de la Enfermedad
/
Gota
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Año:
2018
Tipo del documento:
Article